$1.720
0.000 (0.00%)收盤時
價格預測
在 App 中開啟以解鎖更長週期的預測。
ANVS 相似圖表分析預測
Alphio's ANVS stock price prediction model matches the current Annovis Bio Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $1.70 (-0.91%). The 1-week path is $1.67 (-2.73%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
該買進 Annovis Bio Inc 股票嗎？
Annovis Bio Inc is not a good buy right now due to significant financial losses and low stock price. The current price is $1.72, with a year-to-date change of -52.88% and a negative net income of -17606382 USD in Q1 2026. The upcoming Phase 3 readout poses a risk, as a negative result could severely impact operations and stock value.
ANVS 股價於 Monday 收在 $1.72，此前上漲 0.00%
Annovis Bio Inc (ANVS) last closed at $1.72, gaining +0.00%. These facts feed the 1-day and 1-week ANVS price prediction above.
預測驅動因素
Annovis Bio Inc（ANVS）的預測驅動因素綜合了相似的圖表形態、季節性與移動平均線。
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bearish
相似圖表形態
近期走勢與 ANVS 最接近的股票，依相似度排序。
ANVS 季節性分析
Historically the probability of a positive September return for ANVS is 0.00%. January offers the highest probability of a positive month at 16.39%, while February is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
ANVS 十年價格預測
| 月份 | 最低價 | 平均價 | 最高價 | 潛在報酬率 |
|---|---|---|---|---|
| Sep 2026 | $2.05 | $2.37 | $2.49 | +37.51% |
| Oct 2026 | $2.66 | $3.20 | $3.68 | +86.04% |
| Nov 2026 | $2.81 | $3.15 | $3.38 | +82.85% |
| Dec 2026 | $1.94 | $2.37 | $2.39 | +37.51% |
2026 年，Annovis Bio Inc（ANVS）預計區間為 $1.94 至 $3.68。
Annovis Bio Inc 2026 年月度預測
2026 年 Sep，Annovis Bio Inc 預計均價 $2.37，最低 $2.05，最高 $2.49。
2026 年 Oct，Annovis Bio Inc 預計均價 $3.20，最低 $2.66，最高 $3.68。
2026 年 Nov，Annovis Bio Inc 預計均價 $3.15，最低 $2.81，最高 $3.38。
2026 年 Dec，Annovis Bio Inc 預計均價 $2.37，最低 $1.94，最高 $2.39。
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。